The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, has announced a two-year partnership with Laboratory Corporation of America Holdings (LabCorp). Covance Drug Development will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.
"Covance's commitment to partner with SCRS as a GIP demonstrates that establishing positive site relationships is a high priority for them," said Christine Pierre, SCRS president. "SCRS' GIPs are focused on acknowledging the realities that today's sites face, and actively addressing their challenges. SCRS is proud to welcome Covance as our newest Global Impact Partner."
"Covance is committed to serving the clinical research community as a strong scientific partner in order to speed the development of innovative medicines that meet today's global healthcare needs," said Jill Johnston, global vice president, site activation, informatics and optimization, Covance. "Our work with SCRS will help us better understand the needs of our clinical research partners and ultimately improve service to our pharmaceutical and biotechnology clients."
As a GIP, Covance will participate on the SCRS Global Impact Board at an executive level, and work in tandem with SCRS' Leadership Council in the development and execution of strategic initiatives for SCRS.